News | MRI Breast | May 09, 2019

Screening MRI Detects BI-RADS 3 Breast Cancer in High-risk Patients

Study finds short-interval follow-up MRI may be appropriate for high-risk patients

Screening MRI Detects BI-RADS 3 Breast Cancer in High-risk Patients

May 9, 2019 — When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early-stage breast cancer and avoid unnecessary biopsies, according to a new study. The findings were presented at the American Roentgen Ray Society (ARRS) 2019 Annual Meeting, May 5-10 in Honolulu.

Utilization of MRI for breast cancer screening continues to increase, as it is the most sensitive modality to detect breast cancer. Yet, much more is known about short-term follow-up of probably benign findings (<2 percent of malignancy) for mammography than MRI. The study was conducted to evaluate the frequency and cancer yield of American College of Radiology (ACR) Breast Imaging Reporting and Data System (BI-RADS) 3 lesions in patients undergoing baseline versus non-baseline high-risk screening MRI exams. Non-baseline MRI screening exams were defined as those preceded by at least one screening exam.

Among the 6,672 MRI screening exams performed in 3,214 patients included in the study, 202 (3 percent) were assigned a BI-RADS 3. Among baseline exams, 8.3 percent (82/983) were assigned BI-RADS 3, compared to 2.1 percent (120/5689) of non-baseline exams (p<0.01). Thirteen of 202 (6.4 percent) of the total BI-RADS 3 lesions yielded malignancy, with 12 of the 13 cancers described as either stage 0 or I at diagnosis. Out of 82 baseline exams, the cancer yield of BI-RADS 3 was 2 (2.4 percent), versus 11 of 120 (9.2 percent) on non-baseline exams (p=0.056). Of the 13 diagnosed cancers, eight were initially characterized as foci, three as non-mass enhancement and two as masses. Ten of 13 cancers were upgraded at the six-month follow-up MRI or before.

The results indicate BI-RADS 3 assessments are significantly more common in baseline versus non-baseline screening breast MRI exams, and BI-RADS 3 lesions on baseline exams have a lower cancer yield. Most cancers diagnosed on follow-up of BI-RADS 3 lesions are early stage and most are diagnosed at or before the six-month follow-up. The results indicate that when employed sensibly, short-interval follow-up MRI is an appropriate technique to identify early-stage breast cancer. "This study clarifies that probably benign assessments can be as useful for MRI as they are for mammography," said co-author Leslie Lamb, M.D., MSc, of Massachusetts General Hospital (MGH) and Harvard Medical School, both in Boston.

"Many patients and providers question the utility of BI-RADS 3 in MRI, particularly as some insurers do not cover the costs of the short interval follow-up MRIs. This study clarifies that short interval follow-up MRI is a valuable method of identifying early stage breast cancer while avoiding unnecessary biopsies." noted co-author Christine Edmonds, M.D., of the department of radiology at MGH.

For more information: www.arrs.org

Related Content

New Data Demonstrates Safety Profile of GammaTile Therapy for Various Brain Tumors
News | Brachytherapy Systems | June 18, 2019
GT Medical Technologies Inc. announced the presentation of clinical data from a prospective study of GammaTile Therapy...
Black Men Less Likely to Adopt Active Surveillance for Low-Risk Prostate Cancer
News | Prostate Cancer | June 17, 2019
A new study reveals black men are less likely than white men to adopt an active surveillance strategy for their...
Warm Springs Health & Wellness Center Implements Digisonics Solution for OB Ultrasound
News | Ultrasound Women's Health | June 17, 2019
Warm Springs Health & Wellness Center in Warm Springs, Ore., has selected the Digisonics OB PACS (picture archiving...
International Working Group Releases New Multiple Myeloma Imaging Guidelines

X-ray images such as the one on the left fail to indicate many cases of advanced bone destruction caused by multiple myeloma, says the author of new guidelines on imaging for patients with myeloma and related disorders. Image courtesy of Roswell Park Comprehensive Cancer Center.

News | Computed Tomography (CT) | June 17, 2019
An International Myeloma Working Group (IMWG) has developed the first set of new recommendations in 10 years for...
Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

News | Mammography | June 14, 2019
Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused...
SyMRI Software Receives FDA Clearance for Use With Siemens MRI Systems
Technology | Magnetic Resonance Imaging (MRI) | June 14, 2019
SyntheticMR announced U.S. Food and Drug Administration (FDA) clearance for clinical use of its SyMRI Image and SyMRI...
Ikonopedia Showcases Risk Assessment and Resolution Manager Tools at SIIM and AHRA
News | Mammography Reporting Software | June 13, 2019
Ikonopedia will showcase its suite of structured breast reporting and Mammography Quality Standards Act (MQSA)...
Sponsored Content | Videos | Radiology Imaging | June 13, 2019
In an interview with itnTV, Henry Izawa, vice president, modality solutions and clinical affairs, Fujifilm Medical Sy
iCAD Introduces ProFound AI for 2D Mammography in Europe
News | Artificial Intelligence | June 13, 2019
iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to...
Three Palm Software Releases WorkstationOne Version 1.8.8
Technology | Mammography Reporting Software | June 12, 2019
Three Palm Software announced the release of the 1.8.8 version of its breast imaging workstation, WorkstationOne. This...